Research & resources
Peptide Research Library
Evidence, overviews and practical guides to support informed research.
Browse the Research Library
Search by compound, topic or question
GLP-1, GIP & Glucagon Receptors Explained
GLP-1, GIP and glucagon receptors are different biological targets involved in metabolic signalling. The familiar comparison is that semaglutide targets GLP-1 receptors, tirzepatide…
Read guide →
Peptide Glossary: Scientific Terms, Clearly Explained
New to peptide terminology? Use this glossary to translate the words on product pages, research papers and lab reports into practical questions you…
Read guide →
What Are Peptides? A Plain-Language Beginner’s Guide
Peptides are short chains of amino acids, the building blocks also used to make proteins. Different chains have different roles. Start with what…
Read guide →Peptide compound research directory
Connect a familiar name with its molecular class, research question and evidence limits. Each link opens an existing profile or comparison with original sources. These are not effectiveness rankings. Sequence lengths describe reference entities, not measurements of supplied stock.
| Compound and class | Sequence length | Research path and limit |
|---|---|---|
| BPC-157 Synthetic peptide | 15 residues | Cell migration and tissue-response signalling studied experimentally; no single established clinical target should be assumed. Those experiments do not establish clinical injury recovery or the identity of supplied stock. |
| TB-500 identity Thymosin-related research name requiring an exact structure | Depends on the documented material; the cited identified fragment has 7 residues | A pathway cannot be assigned reliably from an ambiguous label alone. One analysed preparation does not define every material sold under this name. Fragment and full-length evidence are not interchangeable. |
| GHK-Cu Copper-associated tripeptide | 3 peptide residues; copper is not another amino acid | Copper association and matrix-related cell responses; a single universal clinical receptor is not established by the cited experiment. Cell-culture findings do not establish outcomes for systemic administration or every finished topical formula. |
| MOTS-c Mitochondrial-derived peptide | 16 residues | AMPK-related metabolic signalling in the cited cell and mouse work. Natural human measurements are not trials of administering MOTS-c, and mouse results do not establish human performance outcomes. |
| Retatrutide Engineered lipidated peptide | 39 residues | GIP, GLP-1 and glucagon receptor agonism. Read each formulation, population, endpoint and adverse-event record. A research product is not established as equivalent to the studied medicine. |
| Tesamorelin Growth-hormone-releasing factor analogue | 44 residues, with an N-terminal chemical modification | Growth-hormone-releasing hormone receptor pathway. That selected population and medicinal formulation do not establish general weight-loss effects or equivalence of unrelated research material. |
| Ipamorelin Synthetic growth-hormone secretagogue peptide | 5 residues | Ghrelin / growth-hormone secretagogue receptor signalling. A measured hormone response does not establish long-term performance, body-composition or safety claims. |
| KPV Tripeptide fragment related to alpha-MSH | 3 residues | PepT1-mediated uptake and inflammatory signalling in the cited experimental systems. Model-specific findings do not establish a human inflammatory-disease treatment or the finished effects of a KPV-containing blend. |
| CJC-1295 No DAC naming GHRH-related analogue label requiring a confirmed structure | 29 residues for the characterised amidated preparation in the cited analytical paper | GHRH receptor pathway for the defined analogue; attachment of DAC changes the material. The DAC clinical results must not be assigned to a No DAC preparation solely because the names overlap. |
| Tirzepatide Engineered lipidated peptide | 39 residues | GIP and GLP-1 receptor agonism. Study findings are formulation- and population-specific. Similar research names do not establish pharmaceutical equivalence. |
| GLOW Named multi-ingredient blend | No single peptide sequence or residue count | Multiple ingredient-specific pathways; no single blend receptor or verified synergy is inferred. Confirm each ingredient, quantity and chemical form. Total mass does not supply the ratio, compatibility or combination efficacy. |
| KLOW Named multi-ingredient blend | No single peptide sequence or residue count | Multiple ingredient-specific pathways; no single blend receptor or verified synergy is inferred. Confirm each ingredient, quantity and chemical form. Total mass does not supply the ratio, compatibility or combination efficacy. |
| Wolverine Named multi-ingredient blend | No single peptide sequence or residue count | Multiple ingredient-specific pathways; no single blend receptor or verified synergy is inferred. Confirm each ingredient, quantity and chemical form. Total mass does not supply the ratio, compatibility or combination efficacy. |
A related molecule that is not a peptide
NAD+ versus MOTS-c separates a dinucleotide coenzyme from a sixteen-residue peptide. Shared discussion of cellular energy does not make them interchangeable.
Continue with peptide identity, reading research or the COA checklist. Open each profile for source references and the actual study setting.
